Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer
Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
RESONANCE-II trial is a prospective, multicenter, randomized, controlled phase III study
which will enroll 524 patients in total. Patients with eligibility will be registered,
pre-enrolled and receive three cycles of SOX. Then, tumor response evaluation will be carried
out. Those who achieve stable disease or progressive disease will be excluded. Patients
achieving complete response or partial response will be enrolled and assigned into either
group A for another three cycles of SOX (six cycles in total) followed by D2 surgery and
group B for D2 surgery (three cycles in total). The primary endpoint is the rate of
pathological complete response and the secondary endpoints are R0 resection rate, three-year
disease-free survival, five-year overall survival and safety.